Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.
--------
Question: This busy and popular hotel requires a Junior Chef. You will need to be energetic, enthusiastic with a minimum of five years' kitchen experience. You must assist the head and senior chefs in the creation of new dishes. Annual salaries range from 20,000 to 25,000 pounds. Please send or e-mail your CV to the Personnel Administrator Hydo Hotel, Mount Road Eastbourne BN207HZ eclaine.ward@hydrohotel.com. We are looking for a kitchen assistant willing to learn the day-to-day jobs in a professional kitchen environment. You must have a passion for cooking and basic understanding of spoken English. You will mainly be working for a well-known company and learn valuable cheffing skills. The salary will be based on experience but could start from 12,500 pounds to 14,000 pounds annually plus tips. Please forward your CV and a letter of recommendation. 01428644460 Kitchen Manager. Spirit Pub Company is looking for the best individuals to lead our kitchen teams through some very exciting new developments. As an experienced Kitchen Manager, you will play an important role in engaging the chef team by great leaderships to deliver excellent standards and guest satisfaction. We can offer a starting salary of up to 27,000 pounds plus a bonus worth an extra 2,000 pounds per year for the right candidates. If you have what it takes to join our company, please provide your CV with your application. 07044338313 Food Service Assistant, South East Food Service Assistant required. Salary starts from 15,000 pound to 20,000 pounds annually. We are seeking a General Assistant for a Care Home East Sussex. Assisting the Cook and kitchen team in the food preparation of freshly prepared meals, washing up and cleaning of all kitchen areas. Previous experience would be an advantage. 07044338228

Answer: Which job probably offers the second highest salary?

Question: Tanezumab is a humanized monoclonal antibody that specifically inhibits nerve growth factor as a treatment for chronic pain. This phase IIB study investigated the efficacy and safety of tanezumab for chronic low back pain vs placebo and naproxen. Patients (N=1347) received intravenous tanezumab (5, 10, or 20mg every 8weeks), naproxen (500mg twice daily), or placebo. The primary efficacy end point was mean change in daily average low back pain intensity (LBPI) from baseline to week 16. Secondary end points included mean change from baseline to week 16 in the Roland Morris Disability Questionnaire and Patient's Global Assessment (PGA) of low back pain. Tanezumab 10 and 20mg had similar efficacy profiles and significantly improved LBPI, Roland Morris Disability Questionnaire, and PGA scores vs both placebo and naproxen (P.05). Tanezumab 5mg provided improvement of PGA scores vs placebo (P.05), and naproxen resulted in significant improvement of LBPI vs placebo (P.05). Adverse event incidence was comparable across tanezumab doses but higher than with placebo or naproxen. Arthralgia, pain in extremity, headache, and paresthesia were the most commonly reported adverse events by tanezumab-treated patients. The most frequently reported adverse events resulting in discontinuation of tanezumab treatment were arthralgia and paresthesia; the highest frequency was observed with tanezumab 20mg (both 1.4%). Serious adverse event incidence was similar across treatments. In conclusion, tanezumab provided significantly greater improvement in pain, function, and global scores vs placebo and naproxen in patients with chronic low back pain.

Answer: What is the target of tanezumab?

Question: Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has revolutionized the treatment of Bcr-Abl positive chronic myeloid leukemia and become the standard of care for this disease. The aim of this study was evaluation and analysis of cytogenetic response in different intervals and risk groups as well as finding association between pre-treatment characteristics and later probability of achievement of major cytogenetic response. We analyzed a total of 22 adult patients with newly diagnosed Philadelphia positive early chronic phase chronic myeloid leukemia treated at our institution from June 2006 to December 2009. The median follow-up time for patients during treatment with imatinib was 25.7 months (range, 12-42 months). A complete hematologic response was achieved in all of the analyzed patients within 6 months from the start of the treatment. The major cytogenetic response rate was 81.8%, and the complete cytogenetic response rate was 72.7%. The patients with low or moderate relative risk had the rate of complementary achieving major and complete cytogenetic response of 75-90%. A multivariate analysis identified the following independent prognostic factors for achieving major cytogenetic response: the absence of splenomegaly, white blood cell count less than 10 x 10(9)/L, the platelet count less than 450 x 10(9)/L, the presence of less than 5% of bone marrow blasts and basophils, the absence of blasts in peripheral blood, the presence of less than 7% of basophils in peripheral blood. Patients who early achieve complete and major cytogenetic response as well as those with low and moderate relative risk have a higher rate of achieving and maintaining complete cytogenetic response. There are also characteristics of patients before treatment that may indicate the treatment outcome.

Answer:
What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?